BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ribociclib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ribociclib\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT02608216-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Ribociclib: Phase 1 readout est. (NCT02608216)
DESCRIPTION:Ribociclib\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: [18F]FLT PET/CT in Rb+ Metastatic Breast Cancer\nEstimated primary com
 pletion: November 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/ribociclib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT02608216
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03114527-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ribociclib: Phase 2 readout est. (NCT03114527)
DESCRIPTION:Ribociclib\, phase 2.\nStudy: Phase II Trial of Ribociclib and 
 Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarco
 ma (LMS)\nEstimated primary completion: December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/ribociclib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT03114527
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05563220-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20261227
DTEND;VALUE=DATE:20261228
SUMMARY:Ribociclib: Phase 1/2 readout est. (NCT05563220)
DESCRIPTION:Ribociclib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacest
 rant In Various Combination In Participants With Metastatic Breast Cancer\
 nEstimated primary completion: 27 December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/ribociclib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05563220
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05870579-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Ribociclib: Phase 1 readout est. (NCT05870579)
DESCRIPTION:Ribociclib\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Parti
 cipants With ER+\, HER2- and GRPR+ Advanced Breast Cancer\nEstimated prima
 ry completion: 30 December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/ribociclib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05870579
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06239467-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ribociclib: Phase 1 readout est. (NCT06239467)
DESCRIPTION:Ribociclib\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced 
 Breast Cancer\nEstimated primary completion: 31 December 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/ribociclib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06239467
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06481956-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20270110
DTEND;VALUE=DATE:20270111
SUMMARY:Ribociclib: Phase 2 readout est. (NCT06481956)
DESCRIPTION:Ribociclib\, phase 2\, Breast Cancer.\nStudy: T-DM1 Combined Wi
 th CDK4/6 Inhibitor Ribociclib\nEstimated primary completion: 10 January 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/ribociclib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06481956
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05996107-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Ribociclib: Phase 1 readout est. (NCT05996107)
DESCRIPTION:Ribociclib\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Study of Ribociclib Administered Concurrently With Postoperative Radia
 tion Therapy in Patients With High-Risk\, HR+/HER2- Breast Cancer\nEstimat
 ed primary completion: February 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/ribociclib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05996107
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02934568-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Ribociclib: Phase 2 readout est. (NCT02934568)
DESCRIPTION:Ribociclib\, phase 2.\nStudy: Ribociclib (LEE011) Rollover Stud
 y for Continued Access\nEstimated primary completion: 1 February 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/ribociclib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT02934568
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04417621-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20270202
DTEND;VALUE=DATE:20270203
SUMMARY:Ribociclib: Phase 2 readout est. (NCT04417621)
DESCRIPTION:Ribociclib\, phase 2.\nStudy: Study of Efficacy and Safety of L
 XH254 Combinations in Patients With Previously Treated Unresectable or Met
 astatic Melanoma\nEstimated primary completion: 2 February 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/ribociclib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04417621
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01872260-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Ribociclib: Phase 1/2 readout est. (NCT01872260)
DESCRIPTION:Ribociclib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Study of LEE011\, BYL719 and Letrozole in Advanced ER+ Breast Cancer
 \nEstimated primary completion: 26 February 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/ribociclib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT01872260
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06409390-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ribociclib: Phase 2 readout est. (NCT06409390)
DESCRIPTION:Ribociclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cance
 r\nEstimated primary completion: April 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/ribociclib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06409390
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05319873-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Ribociclib: Phase 1/2 readout est. (NCT05319873)
DESCRIPTION:Ribociclib\, phase 1/2\, Breast Cancer.\nStudy: Ribociclib\, Tu
 catinib\, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
 \nEstimated primary completion: 1 April 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/ribociclib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05319873
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05216432-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ribociclib: Phase 1 readout est. (NCT05216432)
DESCRIPTION:Ribociclib\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: First-in-Human Study of Mutant-selective PI3Kα Inhibitor\, RLY-2608\,
  as a Single Agent in Patients With Advanced Solid Tumors and in Combinati
 on With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With 
 Advanced Solid Tumors or Advanced Breast Cancer\nEstimated primary complet
 ion: 30 April 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/r
 ibociclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05216432
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05900206-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ribociclib: Phase 2 readout est. (NCT05900206)
DESCRIPTION:Ribociclib\, phase 2\, Breast Cancer.\nStudy: Trastuzumab Derux
 tecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cance
 r\nEstimated primary completion: 30 April 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/ribociclib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05900206
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06188520-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Ribociclib: Phase 1/2 readout est. (NCT06188520)
DESCRIPTION:Ribociclib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: A First-in-human Dose Escalation and Expansion Study to Evaluate the
  Safety\, and Tolerability of AZD8421 Alone or in Combination in Participa
 nts With Selected Advanced or Metastatic Solid Tumors\nEstimated primary c
 ompletion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/ribociclib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06188520
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03333343-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20270712
DTEND;VALUE=DATE:20270713
SUMMARY:Ribociclib: Phase 1 readout est. (NCT03333343)
DESCRIPTION:Ribociclib\, phase 1.\nStudy: Study of EGF816 in Combination Wi
 th Selected Targeted Agents in EGFR-mutant NSCLC\nEstimated primary comple
 tion: 12 July 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/r
 ibociclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT03333343
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05238922-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20270727
DTEND;VALUE=DATE:20270728
SUMMARY:Ribociclib: Phase 1 readout est. (NCT05238922)
DESCRIPTION:Ribociclib\, phase 1.\nStudy: Study of INCB123667 in Subjects W
 ith Advanced Solid Tumors\nEstimated primary completion: 27 July 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/ribociclib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05238922
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07054190-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Ribociclib: Phase 2 readout est. (NCT07054190)
DESCRIPTION:Ribociclib\, phase 2\, Breast Cancer.\nStudy: A Study to Test I
 navolisib Treatments in Participants With Early-Stage\, PIK3CA-Mutated Bre
 ast Cancer\nEstimated primary completion: 31 July 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/ribociclib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07054190
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04055493-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Ribociclib: Phase 3 readout est. (NCT04055493)
DESCRIPTION:Ribociclib\, phase 3\, Breast Cancer.\nStudy: Adj. Marker-adjus
 ted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Interm
 ediate Risk\, HR+/HER2- EBC\nEstimated primary completion: 31 July 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ribociclib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04055493
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02925234-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Ribociclib: Phase 2 readout est. (NCT02925234)
DESCRIPTION:Ribociclib\, phase 2.\nStudy: The Drug Rediscovery Protocol (DR
 UP Trial)\nEstimated primary completion: September 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/ribociclib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT02925234
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04862663-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Ribociclib: Phase 3 readout est. (NCT04862663)
DESCRIPTION:Ribociclib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2-
  Breast Cancer (CAPItello-292)\nEstimated primary completion: 1 November 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/ribociclib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT04862663
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05683418-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ribociclib: Phase 1 readout est. (NCT05683418)
DESCRIPTION:Ribociclib\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Study to Evaluate the Safety and Tolerability of TOS-358 in Women Wi
 th HR+ HER2- Breast Cancer\nEstimated primary completion: December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ribociclib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05683418
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05508906-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ribociclib: Phase 1 readout est. (NCT05508906)
DESCRIPTION:Ribociclib\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribocicli
 b\, Alpelisib\, Everolimus\, or Atirmociclib in ER+\, HER2- Breast Cancer\
 nEstimated primary completion: 31 December 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/ribociclib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05508906
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07380646-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Ribociclib: Phase 2 readout est. (NCT07380646)
DESCRIPTION:Ribociclib\, phase 2\, Breast Cancer.\nStudy: the Efficacy of L
 eucogen in Preventing the Risk of Ribociclib-Associated Neutropenia in Ear
 ly Breast Cancer\nEstimated primary completion: 1 January 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ribociclib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07380646
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05867251-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Ribociclib: Phase 1/2 readout est. (NCT05867251)
DESCRIPTION:Ribociclib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Study of AVZO-021 in Patients With Advanced Solid Tumors\nEstimated 
 primary completion: 31 January 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/ribociclib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05867251
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07195227-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Ribociclib: Phase 2 readout est. (NCT07195227)
DESCRIPTION:Ribociclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With B
 reast Cancer\nEstimated primary completion: February 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/ribociclib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07195227
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06065748-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20280420
DTEND;VALUE=DATE:20280421
SUMMARY:Ribociclib: Phase 3 readout est. (NCT06065748)
DESCRIPTION:Ribociclib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Study to Evaluate Efficacy and Safety of Giredestrant Compared With 
 Fulvestrant (Plus a CDK4/6 Inhibitor)\, in Participants With ER-Positive\,
  HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Ther
 apy (pionERA Breast Cancer)\nEstimated primary completion: 20 April 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/ribociclib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06065748
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07002177-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Ribociclib: Phase 1/2 readout est. (NCT07002177)
DESCRIPTION:Ribociclib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FW
 D1802 in Patients With ER+/HER2- BC\nEstimated primary completion: 1 May 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/ribociclib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07002177
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06062498-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Ribociclib: Phase 2 readout est. (NCT06062498)
DESCRIPTION:Ribociclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ER
 positive/HER2-negative Advanced or Metastatic Breast Cancer\nEstimated pri
 mary completion: 1 July 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/ribociclib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06062498
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05467891-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20280815
DTEND;VALUE=DATE:20280816
SUMMARY:Ribociclib: Phase 2 readout est. (NCT05467891)
DESCRIPTION:Ribociclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Ribociclib And Endocrine Treatment of Physician's Choice for Locoregio
 nal Recurrent\, Resected Hormone Receptor Positive HER2 Negative Breast Ca
 ncer\nEstimated primary completion: 15 August 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/ribociclib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05467891
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03008408-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Ribociclib: Phase 2 readout est. (NCT03008408)
DESCRIPTION:Ribociclib\, phase 2.\nStudy: A Phase II\, Two-Arm Study of Eve
 rolimus and Letrozole\, +/- Ribociclib (Lee011) in Patients With Advanced 
 or Recurrent Endometrial Carcinoma\nEstimated primary completion: 31 Augus
 t 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/ribociclib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT030084
 08
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06377852-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Ribociclib: Phase 3 readout est. (NCT06377852)
DESCRIPTION:Ribociclib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study\nEstimated primary c
 ompletion: 31 August 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ribociclib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06377852
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06726148-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20280925
DTEND;VALUE=DATE:20280926
SUMMARY:Ribociclib: Phase 1/2 readout est. (NCT06726148)
DESCRIPTION:Ribociclib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Study of ECI830 Single Agent or in Combination in Patients With Adva
 nced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tum
 ors\nEstimated primary completion: 25 September 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/ribociclib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06726148
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06625775-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Ribociclib: Phase 1 readout est. (NCT06625775)
DESCRIPTION:Ribociclib\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors\n
 Estimated primary completion: November 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/ribociclib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06625775
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07618390-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ribociclib: Phase 2 readout est. (NCT07618390)
DESCRIPTION:Ribociclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Phase ll\, Interventional\, Single-arm Study Evaluating the Efficacy
  and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patie
 nts With PIK3CA-mutant\, HR-positive\, HER2-negative Locally Advanced or M
 etastatic Breast Cancer.\nEstimated primary completion: December 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/ribociclib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07618390
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07085767-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ribociclib: Phase 3 readout est. (NCT07085767)
DESCRIPTION:Ribociclib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Palazestrant in Combination With Ribociclib for the First-line Treatme
 nt of ER+/HER2- Advanced Breast Cancer\nEstimated primary completion: Dece
 mber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ribociclib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070
 85767
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05816655-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ribociclib: Phase 2 readout est. (NCT05816655)
DESCRIPTION:Ribociclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Ful
 vestrant + Letrozole + Ribociclib in Hormone Receptor Positive\, HER2 Nega
 tive Metastatic Breast Cancer\nEstimated primary completion: 31 December 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/ribociclib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05816655
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07340658-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Ribociclib: Phase 3 readout est. (NCT07340658)
DESCRIPTION:Ribociclib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Study to Investigate the Efficacy and Safety of Letrozole SIE Compar
 ed With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in P
 ostmenopausal Women With HR-Positive\, HER2-Negative\, Inoperable Locally 
 Advanced or Metastatic Breast Cancer\nEstimated primary completion: Februa
 ry 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/ribociclib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07340
 658
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07647328-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Ribociclib: Phase 3 readout est. (NCT07647328)
DESCRIPTION:Ribociclib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-posi
 tive\, HER2-negative Advanced Breast Cancer\nEstimated primary completion:
  28 February 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ri
 bociclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07647328
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04802759-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20290530
DTEND;VALUE=DATE:20290531
SUMMARY:Ribociclib: Phase 1/2 readout est. (NCT04802759)
DESCRIPTION:Ribociclib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: A Study Evaluating the Efficacy and Safety of Multiple Treatment Com
 binations in Participants With Breast Cancer\nEstimated primary completion
 : 30 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/riboci
 clib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T04802759
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07391774-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Ribociclib: Phase 3 readout est. (NCT07391774)
DESCRIPTION:Ribociclib\, phase 3\, Breast Cancer.\nStudy: Testing Whether H
 ormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by
  Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage 
 Breast Cancer With Low Recurrence Risk\, The RxFINE-Low Trial\nEstimated p
 rimary completion: 31 July 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/ribociclib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07391774
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05203172-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Ribociclib: Phase 4 readout est. (NCT05203172)
DESCRIPTION:Ribociclib\, phase 4.\nStudy: The FLOTILLA Study: Providing Con
 tinued Access to The Study Medicines Encorafenib and Binimetinib for Parti
 cipants in Prior Clinical Trials\nEstimated primary completion: 31 July 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/ribociclib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05203172
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05843253-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Ribociclib: Phase 2 readout est. (NCT05843253)
DESCRIPTION:Ribociclib\, phase 2.\nStudy: Study of Ribociclib and Everolimu
 s in HGG and DIPG or Ribociclib and Temozolomide in DHG\, H3G34-mutant\nEs
 timated primary completion: 31 August 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/ribociclib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05843253
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07164976-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20290901
DTEND;VALUE=DATE:20290902
SUMMARY:Ribociclib: Phase 1/2 readout est. (NCT07164976)
DESCRIPTION:Ribociclib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer\nE
 stimated primary completion: 1 September 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/ribociclib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07164976
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07630948-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20290901
DTEND;VALUE=DATE:20290902
SUMMARY:Ribociclib: Phase 4 readout est. (NCT07630948)
DESCRIPTION:Ribociclib\, phase 4\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Adherence and Safety of Ribociclib Plus Aromatase Inhibitors in Patien
 ts With Early Stage\, HR+ and HER2- Breast Cancer\nEstimated primary compl
 etion: 1 September 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/ribociclib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07630948
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05827081-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20290907
DTEND;VALUE=DATE:20290908
SUMMARY:Ribociclib: Phase 3 readout est. (NCT05827081)
DESCRIPTION:Ribociclib\, phase 3\, Breast Cancer.\nStudy: Phase IIIb Study 
 of Ribociclib + ET in Early Breast Cancer\nEstimated primary completion: 7
  September 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ribo
 ciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05827081
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05296746-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Ribociclib: Phase 2 readout est. (NCT05296746)
DESCRIPTION:Ribociclib\, phase 2\, Breast Cancer.\nStudy: Neoadjuvant and A
 djuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Ca
 ncer\nEstimated primary completion: 1 October 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/ribociclib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05296746
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07767474-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20291028
DTEND;VALUE=DATE:20291029
SUMMARY:Ribociclib: Phase 1/2 readout est. (NCT07767474)
DESCRIPTION:Ribociclib\, phase 1/2.\nStudy: A Study to Evaluate ATX-898 in 
 Participants With Advanced Solid Tumors\nEstimated primary completion: 28 
 October 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ribocic
 lib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07767474
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06380751-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20291218
DTEND;VALUE=DATE:20291219
SUMMARY:Ribociclib: Phase 3 readout est. (NCT06380751)
DESCRIPTION:Ribociclib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy\, Comp
 ared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in 
 HR-Positive\, HER2-Negative (IHC 0\, 1+\, 2+/ ISH Non-amplified)\, BRCA1\,
  BRCA2\, or PALB2m Advanced Breast Cancer\nEstimated primary completion: 1
 8 December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ribo
 ciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06380751
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07400523-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20300210
DTEND;VALUE=DATE:20300211
SUMMARY:Ribociclib: Phase 3 readout est. (NCT07400523)
DESCRIPTION:Ribociclib\, phase 3\, Breast Cancer.\nStudy: Ribociclib in Hor
 mone Receptor-positive\, HER2-negative Early Breast Cancer With Residual D
 isease After Neoadjuvant Chemotherapy\nEstimated primary completion: 10 Fe
 bruary 2030. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ribocicl
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7400523
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03701334-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20300529
DTEND;VALUE=DATE:20300530
SUMMARY:Ribociclib: Phase 3 readout est. (NCT03701334)
DESCRIPTION:Ribociclib\, phase 3\, Breast Cancer.\nStudy: A Trial to Evalua
 te Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Tr
 eatment in Patients With HR+/HER2- Early Breast Cancer\nEstimated primary 
 completion: 29 May 2030. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/ribociclib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT03701334
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05161195-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20300628
DTEND;VALUE=DATE:20300629
SUMMARY:Ribociclib: Phase 4 readout est. (NCT05161195)
DESCRIPTION:Ribociclib\, phase 4\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Roll-over Study to Allow Continued Access to Ribociclib\nEstimated pri
 mary completion: 28 June 2030. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/ribociclib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05161195
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05768139-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Ribociclib: Phase 1/2 readout est. (NCT05768139)
DESCRIPTION:Ribociclib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in C
 ombination With Other Antineoplastic Agents in Participants With Advanced 
 Solid Tumors\nEstimated primary completion: July 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/ribociclib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05768139
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953882-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Ribociclib: Phase 2 readout est. (NCT06953882)
DESCRIPTION:Ribociclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Impact of Omitting Chemo Based on Patient's Selection for ER-Positive\
 , HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy\nEstim
 ated primary completion: September 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/ribociclib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06953882
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03424005-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Ribociclib: Phase 1/2 readout est. (NCT03424005)
DESCRIPTION:Ribociclib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: A Study Evaluating the Efficacy and Safety of Multiple Treatment Com
 binations in Patients With Metastatic or Locally Advanced Breast Cancer\nE
 stimated primary completion: 30 September 2030. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/ribociclib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT03424005
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07423611-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20301001
DTEND;VALUE=DATE:20301002
SUMMARY:Ribociclib: Phase 2 readout est. (NCT07423611)
DESCRIPTION:Ribociclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Ther
 apy in HR-Positive/HER2-Negative Breast Cancer\nEstimated primary completi
 on: 1 October 2030. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/r
 ibociclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07423611
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02813135-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Ribociclib: Phase 1/2 readout est. (NCT02813135)
DESCRIPTION:Ribociclib\, phase 1/2.\nStudy: European Proof-of-Concept Thera
 peutic Stratification Trial of Molecular Anomalies in Relapsed or Refracto
 ry Tumors\nEstimated primary completion: February 2031. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/ribociclib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT02813135
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06849947-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20310630
DTEND;VALUE=DATE:20310701
SUMMARY:Ribociclib: Phase 2 readout est. (NCT06849947)
DESCRIPTION:Ribociclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recur
 red After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in
  HR+\, HER2- Metastatic Breast Cancer\nEstimated primary completion: 30 Ju
 ne 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/ribociclib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06849
 947
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07237256-2228@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20331130
DTEND;VALUE=DATE:20331201
SUMMARY:Ribociclib: Phase 3 readout est. (NCT07237256)
DESCRIPTION:Ribociclib\, phase 3\, Breast Cancer.\nStudy: Chemotherapy De-e
 scalation in HR +\, HER2-\, Intermediate-risk Early Breast Cancer Treated 
 With Adjuvant Ribociclib\nEstimated primary completion: 30 November 2033. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/ribociclib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07237256
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
